John C. Jacobs - Mar 1, 2024 Form 4 Insider Report for NOVAVAX INC (NVAX)

Role
President and CEO, Director
Signature
/s/ Mark J. Casey, Attorney-in-Fact
Stock symbol
NVAX
Transactions as of
Mar 1, 2024
Transactions value $
$0
Form type
4
Date filed
3/26/2024, 06:11 PM
Previous filing
Jan 25, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NVAX Stock Option (Right to Buy) Award $0 +500K $0.00 500K Mar 1, 2024 Common Stock 500K $5.39 Direct F1
transaction NVAX Restricted Stock Units Award $0 +250K $0.00 250K Mar 1, 2024 Common Stock 250K Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Twenty-five percent (25%) of the shares subject to this option grant under the Novavax, Inc. (the "Company") Amended and Restated 2015 Stock Incentive Plan, as amended (the "Plan"), will vest on the first anniversary of the March 1, 2024 grant date (the "Grant Date"), and the remaining seventy-five percent (75%) of the shares will vest in equal monthly installments over the following three (3) years, in each case subject to continued employment through such vesting date.
F2 Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Company's common stock.
F3 One-third (1/3) of the RSUs subject to this grant under the Plan will vest on each of the first three (3) anniversaries of the March 1, 2024 Grant Date, in each case subject to continued employment through such vesting date.